clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Tuberculosis D014376 20 associated lipids
Stomach Ulcer D013276 75 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Otitis Media D010033 12 associated lipids
Carcinoma, Basal Cell D002280 6 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Adenocarcinoma D000230 166 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Stomach Diseases D013272 7 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Skin Neoplasms D012878 12 associated lipids
Colitis D003092 69 associated lipids
Leishmaniasis, Visceral D007898 13 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Arthritis D001168 41 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Abscess D000038 13 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Heart Failure D006333 36 associated lipids
Ureteral Obstruction D014517 10 associated lipids
Rodent Diseases D012376 4 associated lipids
Osteomyelitis D010019 10 associated lipids
Pancreatitis D010195 10 associated lipids
Skin Ulcer D012883 6 associated lipids
Cysts D003560 4 associated lipids
Urination Disorders D014555 9 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Abnormalities, Drug-Induced D000014 10 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Bradycardia D001919 13 associated lipids
Endometriosis D004715 29 associated lipids
Myocardial Infarction D009203 21 associated lipids
Proteinuria D011507 30 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Arteriosclerosis D001161 86 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Fractures, Open D005597 3 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Fibrosis D005355 23 associated lipids
Tooth Discoloration D014075 7 associated lipids
Sinusitis D012852 9 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Enterocolitis, Pseudomembranous D004761 8 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Cross Infection D003428 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Wound Infection D014946 12 associated lipids
Bacteriuria D001437 7 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Periodontal Pocket D010514 9 associated lipids
Ischemia D007511 18 associated lipids
Neuromuscular Diseases D009468 10 associated lipids
Peptic Ulcer D010437 19 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Periodontitis D010518 22 associated lipids
Nasal Polyps D009298 26 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Dermatomycoses D003881 17 associated lipids
Fever D005334 35 associated lipids
Otitis Media with Effusion D010034 9 associated lipids
Bronchial Spasm D001986 18 associated lipids
Hyperlipidemias D006949 73 associated lipids
Bronchitis D001991 6 associated lipids
Shock, Septic D012772 11 associated lipids
Iritis D007500 2 associated lipids
Syphilis D013587 6 associated lipids
Obstetric Labor, Premature D007752 9 associated lipids
Hearing Disorders D006311 10 associated lipids
Duodenitis D004382 4 associated lipids
Metaplasia D008679 7 associated lipids
Foot Diseases D005534 4 associated lipids
Lung Diseases, Obstructive D008173 10 associated lipids
Radiation Injuries D011832 14 associated lipids
Urticaria D014581 13 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Tuberculosis, Pulmonary D014397 18 associated lipids
HIV Seropositivity D006679 15 associated lipids
Endophthalmitis D009877 12 associated lipids
Leprosy D007918 8 associated lipids
Bronchial Hyperreactivity D016535 15 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Paronychia D010304 3 associated lipids
Dyspnea D004417 10 associated lipids
Pyelonephritis D011704 5 associated lipids
Angina Pectoris D000787 27 associated lipids
Klebsiella Infections D007710 7 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Green PA et al. Mycobacterium avium complex parotid lymphadenitis: successful therapy with clarithromycin and ethambutol. 1993 Pediatr. Infect. Dis. J. pmid:8346008
Syrogiannopoulos GA et al. Two dosages of clarithromycin for five days, amoxicillin/clavulanate for five days or penicillin V for ten days in acute group A streptococcal tonsillopharyngitis. 2004 Pediatr. Infect. Dis. J. pmid:15361727
Klein JO Clarithromycin: where do we go from here? 1993 Pediatr. Infect. Dis. J. pmid:8295817
Hardy DJ Extent and spectrum of the antimicrobial activity of clarithromycin. 1993 Pediatr. Infect. Dis. J. pmid:8295818
Prechtl J et al. Monitoring of antibiotic resistance rates of Helicobacter pylori in Austrian children, 2002-2009. 2012 Pediatr. Infect. Dis. J. pmid:22094633
Kuhn SM et al. Treatment of Mycobacterium marinum facial abscess using clarithromycin. 1995 Pediatr. Infect. Dis. J. pmid:7567299
Klein JO History of macrolide use in pediatrics. 1997 Pediatr. Infect. Dis. J. pmid:9109154
Al Soub H et al. Myocardial abscess and bacteremia complicating Mycobacterium fortuitum pacemaker infection: case report and review of the literature. 2009 Pediatr. Infect. Dis. J. pmid:19859019
Chaturvedi S et al. Hemolytic uremic syndrome caused by Bordetella pertussis infection. 2010 Pediatr. Nephrol. pmid:20145955
Galarza M et al. Pediatric granulomatous cerebral amebiasis: a delayed diagnosis. 2002 Pediatr. Neurol. pmid:11897483
Glatstein M et al. Lung abscess due to non-tuberculous, non-Mycobacterium fortuitum in a neonate. 2012 Pediatr. Pulmonol. pmid:22451300
Colin AA and Ali-Dinar T Aerosolized amikacin and oral clarithromycin to eradicate Mycobacterium abscessus in a patient with cystic fibrosis: an 8-year follow-up. 2010 Pediatr. Pulmonol. pmid:20503290
Liu X et al. High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. 2009 Pediatr. Pulmonol. pmid:19360846
Iwanaga K and Carter ER Mycobacterium abscessus complex lung infection in a toddler with a tracheostomy. 2014 Pediatr. Pulmonol. pmid:23460506
Ordoñez CL et al. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. 2001 Pediatr. Pulmonol. pmid:11416873
Robinson P et al. Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial. 2012 Pediatr. Pulmonol. pmid:22266895
Bitzan M et al. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. 2009 Pediatr. Pulmonol. pmid:19681063
Kurz H et al. Role of Chlamydophila pneumoniae in children hospitalized for community-acquired pneumonia in Vienna, Austria. 2009 Pediatr. Pulmonol. pmid:19670403
Colin AA Eradication of mycobacterium abscessus in a chronically infected patient with cystic fibrosis. 2000 Pediatr. Pulmonol. pmid:10973047
Kato S et al. Omeprazole-based dual and triple regimens for Helicobacter pylori eradication in children. 1997 Pediatrics pmid:9200377
Madadi P et al. Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. 2010 Pediatrics pmid:20837591
Bitnun A et al. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. 2003 Pediatrics pmid:14523209
Broussard CS et al. Exposure to antibiotics in a United States-Mexico border birth cohort. 2010 Pediatrics pmid:20457685
Ozdemir R et al. Clarithromycin in preventing bronchopulmonary dysplasia in Ureaplasma urealyticum-positive preterm infants. 2011 Pediatrics pmid:22123897
Moshkowitz M et al. One-week triple therapy with omeprazole, clarithromycin, and nitroimidazole for Helicobacter pylori infection in children and adolescents. 1998 Pediatrics pmid:9651466
Giacometti A et al. Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. 2000 Peptides pmid:11035200
Giacometti A et al. In vitro activity of amphibian peptides alone and in combination with antimicrobial agents against multidrug-resistant pathogens isolated from surgical wound infection. 2005 Peptides pmid:16269345
Giacometti A et al. In vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 2002 Peptides pmid:12084535
Tse KC et al. Delusion of worm infestation associated with clarithromycin in a patient on peritoneal dialysis. 2001 Jul-Aug Perit Dial Int pmid:11587409
Curry EM et al. CAPD peritonitis caused by Mycobacterium rhodesiae. 2008 Jan-Feb Perit Dial Int pmid:18178955
Verbanck JJ et al. Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. 1999 Jan-Feb Perit Dial Int pmid:10201350
Kazama I and Maruyama Y Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes. 2013 Pharm Biol pmid:23527897
Hassan ST et al. In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. 2016 Pharm Biol pmid:26731378
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Alkhalidi BA et al. Development of a predictive in vitro dissolution for clarithromycin granular suspension based on in vitro-in vivo correlations. 2010 Pharm Dev Technol pmid:22716469
Matuz M et al. Non-prescription antibiotic use in Hungary. 2007 Pharm World Sci pmid:17530434
Becker ML et al. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. 2007 Pharm World Sci pmid:17187223
Sancar M et al. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens. 2006 Pharm World Sci pmid:17066247
Ufuk A et al. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. 2015 Pharm. Res. pmid:26224396
Dimer F et al. Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. 2015 Pharm. Res. pmid:26113237
Vehring R Pharmaceutical particle engineering via spray drying. 2008 Pharm. Res. pmid:18040761
Kita T et al. CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. 2001 Pharm. Res. pmid:11465416
Haghi M et al. Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. 2015 Pharm. Res. pmid:25537341
Lu MY et al. A polymer carrier system for taste masking of macrolide antibiotics. 1991 Pharm. Res. pmid:1829521
Rotsch TD et al. Determination of clarithromycin as a contaminant on surfaces by high-performance liquid chromatography using electrochemical detection. 1991 Pharm. Res. pmid:1833731
Meng Y et al. Multi-functional Liposomes Enhancing Target and Antibacterial Immunity for Antimicrobial and Anti-Biofilm Against Methicillin-Resistant Staphylococcus aureus. 2016 Pharm. Res. pmid:26666773
Takeuchi T et al. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. 2006 Pharm. Res. pmid:16779700
Rose WE et al. Prevention of biofilm formation by methacrylate-based copolymer films loaded with rifampin, clarithromycin, doxycycline alone or in combination. 2015 Pharm. Res. pmid:24934663
Craig AM et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. 1996 Pharmacoeconomics pmid:10160472
Agro K et al. Cost effectiveness in Canada of a multidrug prepackaged regimen (Hp-PAC)+ for Helicobacter pylori eradication. 2001 Pharmacoeconomics pmid:11596835
Plosker GL and Figgitt DP Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. 2004 Pharmacoeconomics pmid:15099124
Allen LaPointe NM et al. Frequency of high-risk use of QT-prolonging medications. 2006 Pharmacoepidemiol Drug Saf pmid:16178046
Quach C et al. Effectiveness of amoxicillin, azithromycin, cefprozil and clarithromycin in the treatment of acute otitis media in children: a population-based study. 2005 Pharmacoepidemiol Drug Saf pmid:15386697
Galatti L et al. Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug-drug interactions: a four-year analysis from Italian general practice. 2007 Pharmacoepidemiol Drug Saf pmid:17323404
Corrao G et al. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. 2005 Pharmacoepidemiol Drug Saf pmid:15390219
Drinkard CR et al. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. 2000 Pharmacoepidemiol Drug Saf pmid:11338912
Bérard A et al. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. 2015 Pharmacoepidemiol Drug Saf pmid:26513406
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Karczewska E et al. Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland. 2011 Pharmacol Rep pmid:21857091
Szałek E et al. Sunitinib in combination with clarithromycin or azithromycin - is there a risk of interaction or not? 2012 Pharmacol Rep pmid:23406766
Yamamoto K et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. 2016 Pharmacol. Res. pmid:27468646
Calabresi L et al. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. 2004 Pharmacol. Res. pmid:14998561
Pauwels O Factors contributing to carbamazepine-macrolide interactions. 2002 Pharmacol. Res. pmid:12030792
Woo PC et al. Clarithromycin attenuates cyclophosphamide-induced mucositis in mice. 2000 Pharmacol. Res. pmid:10753551
Marjanović N et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. 2011 Pharmacol. Res. pmid:21315154
Woo PC et al. Clarithromycin attenuates the inflammatory response induced by surgical trauma in a guinea pig model. 1999 Pharmacol. Res. pmid:10051377
Jokinen MJ et al. Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. 2001 Pharmacol. Toxicol. pmid:11322176
Kitano M et al. Effects of clarithromycin and dexamethasone on mucus production in isografted rat trachea. 2011 Pharmacology pmid:21228611
Schulz-Du Bois C et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. 2008 Pharmacopsychiatry pmid:19067264
Najib MM et al. Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia. 2000 Pharmacotherapy pmid:10772376
Mertl SL The role of clarithromycin in the prophylaxis of disseminated Mycobacterium avium-intracellulare infection in patients with AIDS. 1996 May-Jun Pharmacotherapy pmid:8726597
Mor N et al. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. 1994 Jan-Feb Pharmacotherapy pmid:8159593
Auclair B et al. Potential interaction between itraconazole and clarithromycin. 1999 Pharmacotherapy pmid:10600094
Khamaisi M and Leitersdorf E Severe hypoglycemia from clarithromycin-repaglinide drug interaction. 2008 Pharmacotherapy pmid:18447665
Otsuka SH Severe hypoglycemia from Helicobacter pylori triple-drug therapy and insulin detemir drug interaction. 2013 Pharmacotherapy pmid:23471710
Nicholson SC et al. Antimicrobial-associated acute hepatitis. 2002 Pharmacotherapy pmid:12066973
Gaylor AS and Reilly JC Therapy with macrolides in patients with cystic fibrosis. 2002 Pharmacotherapy pmid:11837560
Adelglass J et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. 1998 Nov-Dec Pharmacotherapy pmid:9855324
Kang-Birken SL and Prichard JG Mycobacterium szulgai in a patient with advanced acquired immunodeficiency syndrome: an unusual pathogen with unusual multidrug resistance. 2006 Pharmacotherapy pmid:17064210
Guerriero SE et al. Two cases of clarithromycin-induced digoxin toxicity. 1997 Sep-Oct Pharmacotherapy pmid:9324195
McConnell SA and Amsden GW Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. 1999 Pharmacotherapy pmid:10212011
Molden E and Andersson KS Simvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patients. 2007 Pharmacotherapy pmid:17381388
Oberg KC Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. 1998 Mar-Apr Pharmacotherapy pmid:9545160
Shin J et al. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. 2011 Pharmacotherapy pmid:21950641
Stein GE et al. A preliminary study of clarithromycin versus doxycycline in the treatment of nongonococcal urethritis and mucopurulent cervicitis. 1995 Nov-Dec Pharmacotherapy pmid:8602379
Stein GE and Schooley S Serum bactericidal activity of extended-release clarithromycin against macrolide-resistant strains of Streptococcus pneumoniae. 2002 Pharmacotherapy pmid:12013358
Sketris IS et al. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. 1996 Mar-Apr Pharmacotherapy pmid:8820476
Legendre DP et al. Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. 2012 Pharmacotherapy pmid:22392826
Guo D et al. The cardiotoxicity of macrolides: a systematic review. 2010 Pharmazie pmid:21038838
Valizadeh H et al. Antibacterial activity of clarithromycin loaded PLGA nanoparticles. 2012 Pharmazie pmid:22393833
Togami K et al. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. 2012 Pharmazie pmid:22764569
Hamdan II Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II). 2003 Pharmazie pmid:12685822
Lohitnavy M et al. Pharmacokinetic and bloequivalence studies of generic clarithromycin tablets in healthy male volunteers. 2003 Pharmazie pmid:12622260
Chadha R et al. Quantitative analysis of in vitro compatibility of binary and ternary mixtures of nitroimidazole and macrolides in combination with omeprazole using a calorimetric technique. 2007 Pharmazie pmid:17557738
Kim PK and Dorshimer GW Case report: peptic ulcer disease in a professional athlete. 2009 Phys Sportsmed pmid:20048520
Celik H and Ayar A Clarithromycin inhibits myometrial contractions in isolated human myometrium independent of stimulus. 2002 Physiol Res pmid:12234115
Stege PW et al. Antimicrobial activity of aqueous extracts of Larrea divaricata Cav (jarilla) against Helicobacter pylori. 2006 Phytomedicine pmid:17085295
Dabos KJ et al. The effect of mastic gum on Helicobacter pylori: a randomized pilot study. 2010 Phytomedicine pmid:19879118
Nostro A et al. Effects of combining extracts (from propolis or Zingiber officinale) with clarithromycin on Helicobacter pylori. 2006 Phytother Res pmid:16521108
Lawal TO et al. Combination studies of Eucalyptus torelliana F. Muell. leaf extracts and clarithromycin on Helicobacter pylori. 2012 Phytother Res pmid:22318891